Loading...
Because secondary recurrent miscarriage (RM) is thought to be rooted in immunologic disturbances, many trials of intravenous immunoglobulin (IVIg) have been conducted. However, these trials (and even meta-analyses) have produced conflicting results. To clarify whether IVIg improves the chances of live birth, Danish investigators conducted a randomized, double-blind trial of IVIg (infused 8 times between documentation of rising serum hCG levels and 14–15 weeks' gestation) versus albumin in 82 women with ≥4 miscarriages and no evidence of uterine abnormality.
In intention-to-treat analysis, birth rates were 54.8% in the IVIg group and 50.0% in the placebo group (relative rate, 1.11; P=0.67). After exclusion of five explained pregnancy losses, …